1. Scrip

UK Terminates COVID-19 Vaccine Deal, But Valneva Can Bounce Back

Two Other Vaccines Show Promise

 
• By Andrew McConaghie

The UK’s decision has hit Valneva’s share price hard, but its vaccine candidates in Chikungunya and Lyme’s disease should help the firm bounce back.

Valneva Livingston
Production of the COVID-19 vaccine has begun at Valneva's manufacturing facility in Livingston, Scotland.

The UK government has terminated an agreement to acquire 100 million doses of Valneva’s COVID-19 vaccine candidate, citing a “breach of obligations” by the company.

Valneva “strenuously denies” that it has broken any terms of the procurement deal, which until now has been part of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach

 
• By Mandy Jackson

A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.

Pharma Gets A Compatriot At CDER With Tidmarsh Appointment To Top Spot

 
• By Jessica Merrill

Drug manufacturers may find comfort in the appointment of former biotech CEO and entrepreneur George Tidmarsh to lead the FDA’s Center for Drug Evaluation and Research.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.